Literature DB >> 18428146

Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.

Nassim Kamar1, Catherine Mengelle, Laure Esposito, Joëlle Guitard, Marion Mehrenberger, Laurence Lavayssière, David Ribes, Olivier Cointault, Dominique Durand, Jacques Izopet, Lionel Rostaing.   

Abstract

The aims of the present study were to assess the incidence of cytomegalovirus (CMV) reactivation, and to determine the predictive factors for CMV reactivation in CMV seropositive kidney-transplant patients. One hundred ninety CMV seropositive kidney-transplant patients were included in this study; of these, 39 patients had received CMV prophylaxis. CMV DNAemia was assessed by real-timepolymerase chain reaction assay every 2 weeks until day 120, then every 3-4 weeks until day 180, and then every month until day 365. One hundred seven patients (56.3%) had at least one positive CMV DNAemia within the first year. The time between renal transplantation and the first positive CMV DNAemia was 59 +/- 5 days. The number of positive CMV DNAemia/patient was 3.28 +/- 0.22. CMV viral load at first positive CMV DNAemia was 704 (10-742,000) copies/ml. The donor CMV seropositivity, the absence of CMV prophylaxis, and the occurrence of acute rejection before CMV reactivation were independent factors associated with CMV reactivation within the first year after kidney transplantation. Hence, CMV reactivation is frequent after kidney transplantation. CMV prophylaxis in CMV seropositive kidney-transplant patients should be offered to avoid CMV-related side-effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18428146     DOI: 10.1002/jmv.21176

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.

Authors:  Kavitha Ranganathan; Sarah Worley; Marian G Michaels; Susana Arrigan; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart C Sweet; Albert Faro; Lara Danziger-Isakov
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

2.  The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation.

Authors:  Lara A Danziger-Isakov; Sarah Worley; Marian G Michaels; Susana Arrigain; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart Sweet; Albert Faro
Journal:  Transplantation       Date:  2009-05-27       Impact factor: 4.939

Review 3.  Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Authors:  Estéfani García-Ríos; Marcos Nuévalos; Francisco J Mancebo; Pilar Pérez-Romero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

4.  Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis.

Authors:  T Vilibic-Cavlek; B Kolaric; S Ljubin-Sternak; M Kos; B Kaic; G Mlinaric-Galinovic
Journal:  Indian J Nephrol       Date:  2015 Mar-Apr

Review 5.  Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation.

Authors:  Jan Styczynski
Journal:  Infect Dis Ther       Date:  2017-12-04

6.  Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation.

Authors:  Cahue Henrique Pinto; Helio Tedesco-Silva; Claudia Rosso Felipe; Alexandra Nicolau Ferreira; Marina Cristelli; Laila Almeida Viana; Wilson Aguiar; José Medina-Pestana
Journal:  Braz J Infect Dis       Date:  2016-09-25       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.